Health Tech Investment Act Seeks to Expand Medicare AI Device Reimbursement

The Health Tech Investment Act, a new bipartisan bill in the U.S. Senate, aims to expand Medicare reimbursement for FDA-cleared medical devices that utilize artificial intelligence or machine learning.

The legislation introduces a temporary reimbursement pathway using New Technology Ambulatory Payment Classification codes for up to five years, allowing time for the Centers for Medicare & Medicaid Services to gather clinical data and develop long-term reimbursement policies. Nexalin Technology supports this bill, highlighting its alignment with their AI-driven Gen-3 HALO Clarity device and the bill's potential to enhance innovation and access in healthcare sectors like mental health.